FLT3 and acute myeloid leukemia: Thus, using the appropriate mitigation strategies to prevent excessive myelosuppression, the triplet regimen of azacitidine, venetoclax, and gilteritinib can be delivered safely and represents a highly effective treatment option for older or unfit adults with newly diagnosed FLT3-mutated AML.